Cargando…

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation

OBJECTIVE: This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jian-man, Sun, Lei, Wang, Linjing, Zhou, Tong-Chong, Yuan, Yawei, Zhen, Xin, Liao, Zhi-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008953/
https://www.ncbi.nlm.nih.gov/pubmed/35422007
http://dx.doi.org/10.1186/s13104-022-06019-x
_version_ 1784687172386816000
author Zhu, Jian-man
Sun, Lei
Wang, Linjing
Zhou, Tong-Chong
Yuan, Yawei
Zhen, Xin
Liao, Zhi-Wei
author_facet Zhu, Jian-man
Sun, Lei
Wang, Linjing
Zhou, Tong-Chong
Yuan, Yawei
Zhen, Xin
Liao, Zhi-Wei
author_sort Zhu, Jian-man
collection PubMed
description OBJECTIVE: This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model is essential for accurate treatment outcome prediction. Our study were established 176 discrimination models constructed with 22 feature selection methods and 8 classifiers. The predictive performance of each model were evaluated using the AUC, ACC, sensitivity and specificity, where the optimal model was identified. RESULTS: There were totally 107 radiomics features and 7 clinical features obtained from each patient. After feature selection, the top-ten most relevant features were fed to train 176 models. Significant performance variations were observed in the established models, with the best performance achieved by the logistic regression model using gini-index feature selection (AUC = 0.797, ACC = 0.722, sensitivity = 0.758, specificity = 0.693). The median R-score was 0.518 (IQR, 0.023–0.987), and the patients were divided into high-risk and low-risk groups based on this cut-off value. The KM survival curves of the two groups demonstrated evident stratification results (p = 0.000). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06019-x.
format Online
Article
Text
id pubmed-9008953
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90089532022-04-15 Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation Zhu, Jian-man Sun, Lei Wang, Linjing Zhou, Tong-Chong Yuan, Yawei Zhen, Xin Liao, Zhi-Wei BMC Res Notes Research Note OBJECTIVE: This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model is essential for accurate treatment outcome prediction. Our study were established 176 discrimination models constructed with 22 feature selection methods and 8 classifiers. The predictive performance of each model were evaluated using the AUC, ACC, sensitivity and specificity, where the optimal model was identified. RESULTS: There were totally 107 radiomics features and 7 clinical features obtained from each patient. After feature selection, the top-ten most relevant features were fed to train 176 models. Significant performance variations were observed in the established models, with the best performance achieved by the logistic regression model using gini-index feature selection (AUC = 0.797, ACC = 0.722, sensitivity = 0.758, specificity = 0.693). The median R-score was 0.518 (IQR, 0.023–0.987), and the patients were divided into high-risk and low-risk groups based on this cut-off value. The KM survival curves of the two groups demonstrated evident stratification results (p = 0.000). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06019-x. BioMed Central 2022-04-14 /pmc/articles/PMC9008953/ /pubmed/35422007 http://dx.doi.org/10.1186/s13104-022-06019-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Note
Zhu, Jian-man
Sun, Lei
Wang, Linjing
Zhou, Tong-Chong
Yuan, Yawei
Zhen, Xin
Liao, Zhi-Wei
Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
title Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
title_full Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
title_fullStr Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
title_full_unstemmed Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
title_short Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
title_sort radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with egfr mutation
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008953/
https://www.ncbi.nlm.nih.gov/pubmed/35422007
http://dx.doi.org/10.1186/s13104-022-06019-x
work_keys_str_mv AT zhujianman radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation
AT sunlei radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation
AT wanglinjing radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation
AT zhoutongchong radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation
AT yuanyawei radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation
AT zhenxin radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation
AT liaozhiwei radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation